
AIM ImmunoTech Net Income | AIM
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AIM ImmunoTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 M | -17.3 M | -29 M | -19.4 M | -19.1 M | -14.4 M | -9.53 M | -9.81 M | -8.26 M | -7.5 M | -15.2 M | -17.4 M | -16.2 M | -17.4 M | -9.02 M | -2.5 M | -7.18 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.5 M | -29 M | -13.7 M |
Quarterly Net Income AIM ImmunoTech
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.14 M | -3.79 M | -3.02 M | -4.18 M | -3.28 M | -2.79 M | -3.7 M | -5.97 M | -3.7 M | -1.84 M | -5.82 M | -12.6 M | -7.82 M | -4.91 M | -3.66 M | - | -6.38 M | -4.85 M | -3.82 M | - | -3.83 M | -5.88 M | -3.58 M | - | -3.31 M | -3.37 M | -3.81 M | - | -2.95 M | -2.04 M | -3.36 M | - | -3.08 M | -2.42 M | -2.71 M | - | -1.25 M | -2.19 M | -2.82 M | - | -2.86 M | -1.3 M | -2.16 M | -3.14 M | -3.8 M | -4.84 M | -3.44 M | -4.46 M | -4.2 M | -4.96 M | -3.84 M | -3.2 M | -5.14 M | -4.28 M | -3.61 M | -5.46 M | -6.59 M | -3 M | -2.31 M | -3.12 M | -2.74 M | -2.29 M | -866 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -866 K | -12.6 M | -3.81 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Allena Pharmaceuticals
ALNA
|
-10.4 M | - | 3.16 % | $ 1.9 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-70.8 M | - | -15.15 % | $ 60.3 M | ||
|
TFF Pharmaceuticals
TFFP
|
-21.2 M | - | -60.05 % | $ 125 K | ||
|
Codiak BioSciences
CDAK
|
-37.2 M | - | -55.98 % | $ 2.15 M | ||
|
Sage Therapeutics
SAGE
|
-401 M | - | - | $ 527 M | ||
|
Paratek Pharmaceuticals
PRTK
|
-63.6 M | - | - | $ 121 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-7.26 M | - | - | $ 521 M | ||
|
Cyclerion Therapeutics
CYCN
|
-3.18 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Seelos Therapeutics
SEEL
|
-37.9 M | - | -47.76 % | $ 6.27 M | ||
|
Завод ДИОД
DIOD
|
37.2 M | - | - | - | ||
|
Kiromic BioPharma
KRBP
|
-26.9 M | - | 6.61 % | $ 3.08 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | ||
|
Fusion Pharmaceuticals
FUSN
|
-94.9 M | - | - | $ 1.41 B | ||
|
Gritstone Oncology
GRTS
|
-138 M | - | 0.42 % | $ 213 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | ||
|
Titan Pharmaceuticals
TTNP
|
-4.71 M | - | -3.76 % | $ 3.47 M | ||
|
HOOKIPA Pharma
HOOK
|
-43.5 M | - | -6.92 % | $ 79.4 M | ||
|
Otonomy
OTIC
|
-51.2 M | - | -1.96 % | $ 4.68 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
124 M | $ 286.96 | 0.01 % | $ 5.55 B | ||
|
Фармсинтез
LIFE
|
-525 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
-33.9 M | $ 1.04 | -4.59 % | $ 32.4 M | ||
|
Oncternal Therapeutics
ONCT
|
-39.5 M | - | -24.12 % | $ 1.56 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
Concert Pharmaceuticals
CNCE
|
-80.1 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
-10.6 M | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-64.4 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
25.4 M | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
-3.35 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
-2.03 M | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
-131 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
-173 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
-67.1 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
521 M | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
-114 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
-312 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
-5.02 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
-134 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
-7.83 M | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
-86.1 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
-220 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-582 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
-6.88 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
-40.3 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
-39.6 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
-8.12 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
-77.4 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 0.07 | 9.81 % | $ 855 K |